Wednesday, October 13, 2010

Ben Goldacre - Pfizer got away with Edronax "because the MHRA failed us"



"Conclusions: Reboxetine is, overall, an ineffective and potentially harmful antidepressant. Published evidence is affected by publication bias, underlining the urgent need for mandatory publication of trial data."

Here's the BMJ paper

Insider wonders if Ben will take this further.

No comments: